中晚期宫颈鳞癌患者治疗前外周血Treg计数分析
发布时间：2019-05-29 06:50
【摘要】：背景与目的:中晚期宫颈鳞癌同期放化疗(concurrent chemoradiotherapy,CCRT)治疗前性价比高的疗效判断方法较有限,该研究拟通过检测治疗前外周血CD4+CD25+CD127Low/-调节性T细胞(regulatory T cells,Tregs)亚群计数及血清鳞癌抗原(squamous cell carcinoma antigen,SCC-Ag)水平,评价两者预测临床疗效的可行性。方法:采集44例ⅡB~ⅣA期宫颈鳞癌患者行CCRT治疗前的外周血标本,分别利用流式细胞免疫表型分析和酶联免疫法检测外周血CD4+CD25+CD127Low/-Treg计数及血清SCC-Ag水平。收集临床和病理资料,并统计检验2个指标对疗效的预测作用。结果:治疗前外周血CD4+CD25+CD127Low/-Treg计数在临床有效组低于无效组[(8.78±2.80)%vs(10.95±2.56)%,P0.05],血清SCC-Ag在不同临床疗效组间差异无统计学意义,且这2个指标之间未发现相关性(Spearman’rho=-0.093,P=0.540)。经受试者工作特征(receiver operating characteristic,ROC)曲线确定治疗前外周血CD4+CD25+CD127Low/-Treg及血清SCC-Ag最佳界值分别为9.76%与9.50 ng/m L。单因素分析显示,治疗前外周血CD4+CD25+CD127Low/-Treg计数(OR=1.901,95%CI:1.112~3.219,P=0.017)对CCRT疗效有预测作用,而血清SCC-Ag水平无预测作用(OR=0.998,95%CI:0.001~4.253,P=0.897)。多因素Logistic回归分析显示,治疗前外周血CD4+CD25+CD127Low/-Treg为独立的临床疗效预测因子(OR=3.115,95%CI:1.253~7.742,P=0.014)。结论:治疗前外周血CD4+CD25+CD127Low/-Treg计数用于中晚期宫颈鳞癌患者CCRT临床疗效预测具有可行性。
[Abstract]:Background & objective: the method of evaluating the performance-price ratio of advanced cervical carcinoma with concurrent radiotherapy and chemotherapy (concurrent chemoradiotherapy,CCRT) is limited. This study aims to detect (regulatory T cells, of CD4 CD25 CD127Low/- regulatory T cells in peripheral blood before treatment. The feasibility of predicting clinical efficacy was evaluated by the count of Tregs) subsets and the level of serum squamous cell carcinoma antigen (squamous cell carcinoma antigen,SCC-Ag). Methods: peripheral blood samples were collected from 44 patients with stage II B ~ IV A cervical squamous cell carcinoma before CCRT treatment. Flow cytometry and enzyme linked immunosorbent assay (Elisa) were used to detect CD4 CD25 CD127Low/-Treg count and serum SCC-Ag level in peripheral blood. The clinical and pathological data were collected and the predictive effects of the two indexes on the curative effect were statistically tested. Results: the CD4 CD25 CD127Low/-Treg count of peripheral blood in the clinical effective group was lower than that in the ineffective group [(8.78 卤2.80)% vs (10.95 卤2.56)%, P 0.05]. There was no significant difference in serum SCC-Ag among different clinical efficacy groups. No correlation was found between the two indexes (Spearman'rho=-0.093,P=0.540). The optimal boundary values of CD4 CD25 CD127Low/-Treg and SCC-Ag in peripheral blood before treatment were 9.76% and 9.50 ng/m 路L ~ (- 1), respectively, according to the working characteristic CD4 CD25 CD127Low/-Treg) curve of the subjects. Univariate analysis showed that CD4 CD25 CD127Low/-Treg count (OR=1.901,95%CI:1.112~3.219,P=0.017) in peripheral blood before treatment could predict the curative effect of CCRT, but serum SCC-Ag level had no predictive effect (OR=0.998,95%CI:0.001~4.253,). P 鈮，
本文编号：2487742
[Abstract]:Background & objective: the method of evaluating the performance-price ratio of advanced cervical carcinoma with concurrent radiotherapy and chemotherapy (concurrent chemoradiotherapy,CCRT) is limited. This study aims to detect (regulatory T cells, of CD4 CD25 CD127Low/- regulatory T cells in peripheral blood before treatment. The feasibility of predicting clinical efficacy was evaluated by the count of Tregs) subsets and the level of serum squamous cell carcinoma antigen (squamous cell carcinoma antigen,SCC-Ag). Methods: peripheral blood samples were collected from 44 patients with stage II B ~ IV A cervical squamous cell carcinoma before CCRT treatment. Flow cytometry and enzyme linked immunosorbent assay (Elisa) were used to detect CD4 CD25 CD127Low/-Treg count and serum SCC-Ag level in peripheral blood. The clinical and pathological data were collected and the predictive effects of the two indexes on the curative effect were statistically tested. Results: the CD4 CD25 CD127Low/-Treg count of peripheral blood in the clinical effective group was lower than that in the ineffective group [(8.78 卤2.80)% vs (10.95 卤2.56)%, P 0.05]. There was no significant difference in serum SCC-Ag among different clinical efficacy groups. No correlation was found between the two indexes (Spearman'rho=-0.093,P=0.540). The optimal boundary values of CD4 CD25 CD127Low/-Treg and SCC-Ag in peripheral blood before treatment were 9.76% and 9.50 ng/m 路L ~ (- 1), respectively, according to the working characteristic CD4 CD25 CD127Low/-Treg) curve of the subjects. Univariate analysis showed that CD4 CD25 CD127Low/-Treg count (OR=1.901,95%CI:1.112~3.219,P=0.017) in peripheral blood before treatment could predict the curative effect of CCRT, but serum SCC-Ag level had no predictive effect (OR=0.998,95%CI:0.001~4.253,). P 鈮，
本文编号：2487742
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2487742.html
最近更新
教材专著
